A data-driven study of Alzheimer's disease related amyloid and tau pathology progression
Open Access
- 11 July 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 146 (12) , 4935-4948
Abstract
Amyloid-β is thought to facilitate the spread of tau throughout the neocortex in Alzheimer's disease, though how this occurs is not well understood. This is because of the spatial discordance between amyloid-β, which accumulates in the neocortex, and tau, which accumulates in the medial temporal lobe during ageing. There is evidence that in some cases amyloid-β-independent tau spreads beyond the medial temporal lobe where it may interact with neocortical amyloid-β. This suggests that there may be multiple distinct spatiotemporal subtypes of Alzheimer's-related protein aggregation, with potentially different demographic and genetic risk profiles. We investigated this hypothesis, applying data-driven disease progression subtyping models to post-mortem neuropathology and in vivo PET-based measures from two large observational studies: the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Religious Orders Study and Rush Memory and Aging Project (ROSMAP). We consistently identified ‘amyloid-first’ and ‘tau-first’ subtypes using cross-sectional information from both studies. In the amyloid-first subtype, extensive neocortical amyloid-β precedes the spread of tau beyond the medial temporal lobe, while in the tau-first subtype, mild tau accumulates in medial temporal and neocortical areas prior to interacting with amyloid-β. As expected, we found a higher prevalence of the amyloid-first subtype among apolipoprotein E (APOE) ε4 allele carriers while the tau-first subtype was more common among APOE ε4 non-carriers. Within tau-first APOE ε4 carriers, we found an increased rate of amyloid-β accumulation (via longitudinal amyloid PET), suggesting that this rare group may belong within the Alzheimer's disease continuum. We also found that tau-first APOE ε4 carriers had several fewer years of education than other groups, suggesting a role for modifiable risk factors in facilitating amyloid-β-independent tau. Tau-first APOE ε4 non-carriers, in contrast, recapitulated many of the features of primary age-related tauopathy. The rate of longitudinal amyloid-β and tau accumulation (both measured via PET) within this group did not differ from normal ageing, supporting the distinction of primary age-related tauopathy from Alzheimer's disease. We also found reduced longitudinal subtype consistency within tau-first APOE ε4 non-carriers, suggesting additional heterogeneity within this group. Our findings support the idea that amyloid-β and tau may begin as independent processes in spatially disconnected regions, with widespread neocortical tau resulting from the local interaction of amyloid-β and tau. The site of this interaction may be subtype-dependent: medial temporal lobe in amyloid-first, neocortex in tau-first. These insights into the dynamics of amyloid-β and tau may inform research and clinical trials that target these pathologies.Keywords
All Related Versions
Funding Information
- European Union’s Horizon 2020 research (666992)
- National Institute of Biomedical Imaging and Bioengineering
- National Institutes of Health (P41EB015922)
- National Institute on Aging of the National Institutes of Health (P30AG066530)
- UKRI Future Leaders Fellow (MRC MR/S03546X/1)
- National Institute for Health Research
- University College London Hospitals Biomedical Research Centre
- Medical Research Council Skills Development Fellowship (MR/T027770/1)
- MRC Skills Development Fellowship (MR/T027800/1)
- EPSRC (EP/M020533/1)
- Medical Research Council eMedLab Medical Bioinformatics Career Development Fellowship
- Medical Research Council (MR/L016311/1)
- EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (115952)
- European Union’s Horizon 2020 research and innovation program and EFPIA
- IMI
- European Union
- EFPIA
- GE Healthcare
This publication has 54 references indexed in Scilit:
- Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathologyNeurology, 2013
- Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective studyThe Lancet Neurology, 2011
- Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's diseaseNature Genetics, 2009
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Frequency of Stages of Alzheimer-Related Lesions in Different Age CategoriesNeurobiology of Aging, 1997
- Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s DiseaseNeurobiology of Aging, 1997
- Alzheimer's Disease: The Amyloid Cascade HypothesisScience, 1992
- Neuropathological stageing of Alzheimer-related changesActa Neuropathologica, 1991
- The molecular pathology of Alzheimer's diseaseNeuron, 1991
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984